The DC Team
Paul D. Lyons, MD, PhD
President & Chief Medical Officer
Paul D. Lyons, MD, Ph.D. is Chief Medical Officer and President of Dominion Cannabinoids, LLC. He supports the scientific portfolio through the active design of preclinical and clinical studies as well as focusing on manipulation of CNS inflammatory and excitatory processes.
Dr. Lyons completed his doctoral work at the University of Alabama Birmingham in the Department of Physiology and Biophysics where he studied mechanisms of cellular communication of neuropeptides in immune cells. There, he also performed a postdoctoral fellowship in the Department of Cell Biology, studying the role of soluble adhesions molecules from astrocytes in Alzheimer's disease pathology.
While obtaining a medical degree, he also engaged in human genetic research, identifying genetic risk factors for schizophrenia using novel techniques of population admixture and endophenotypes.
As a practicing epileptologist, he spent the last decade studying molecules of cannabinoids in pediatric and adult epilepsy. Dr. Lyons has authored numerous peer-reviewed publications including articles in Epilepsia as well as The Lancet.
Bret Bader
Partner
Bret is an experienced business leader with a strong background in sensor and detection technology. Bret has been the CEO of Owlstone Inc. since 2006. In his role as CEO, Bret leads the strategic planning, and execution of all business functions as the organization reaches for full potential. Bret is also a sought-after business advisor and is currently on the Board of Directors of multiple enterprises where he contributes his significant experience in business planning, messaging, and capital raise. Bret takes pride in helping to shape and guide innovative ideas toward a common definition of success and value creation.
Julien Dimastromatteo, PhD
Chief Research Officer
Dr. Dimastromatteo boasts an impressive background in molecular imaging and pharmaceutical development, with his research focusing on the development and application of small molecules and biologics for a variety of health conditions, including cancer, asthma, inflammatory bowel disorders, diabetes, and autoimmune diseases. His previous roles include serving as a Research Instructor at the University of Virginia (UVA) and holding the position of Principal Scientist Officer at ZielBio, where he played a crucial role as a co-inventor of a patented immunotherapy. Julien was also Vice President Drug Discovery at Adovate where he lead IND-enabling programs. Dr. Dimastromatteo pursued his academic journey at the Université des Alpes (previously known as Joseph Fourier), achieving a License Degree in Cellular Biology & Physiology, a Masters in Medical Imaging, and a PhD in Biomedical Engineering. In 2023, Julien was inducted full member of Sigma Xi, The Scientific Research Honor Society.